ClinicalTrials.Veeva

Menu
C

Clinical Best Solutions | Lublin, PL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Olezarsen
Bococizumab
Mevrometostat
Cariprazine
Abiraterone
LY3502970
BI 690517
Dapagliflozin
Triglycerides
Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 16 total trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abiraterone

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in p...

Active, not recruiting
Type 2 Diabetes
Drug: Orforglipron
Drug: Dapagliflozin

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alon...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: PF-06821497
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Placebo
Drug: Muvalaplin

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

Trial sponsors

Lilly logo
Boehringer Ingelheim logo
Pfizer logo
Ionis Pharmaceuticals logo
A
A
Forest Laboratories logo
Kowa logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems